Classification of arthrogryposis

Judith G. Hall1, Eva Kimber2, Klaus Dieterich3

1Department of Medical Genetics and Pediatrics, University of British Columbia and BC Children’s Hospital, Vancouver, British Columbia, Canada
2Department of Pediatrics, Institute of Clinical Sciences at Sahlgrenska Academy, The Queen Silvia Children’s Hospital, Gothenburg, Sweden
3Grenoble Institut des neurosciences, University of Grenoble La Tronche, France

Abstract
There is a need for a system to classify various forms of arthrogryposis. None is satisfactory or complete. Nevertheless, several have been developed to meet the needs of clinicians, prenatal diagnosticians, researchers, and basic scientists. They all await more insight into basic mechanisms.

Keywords
arthrogryposis, classification, clinical approach, molecular approach, tissue disorders

1 | BACKGROUND

Arthrogryposis (AMC) also known as multiple congenital contractures (MCCs) is a very heterogeneous group of disorders. It is really a sign rather than a diagnosis. The only common thread is that all of the conditions and affected individuals have had decreased fetal movement in utero. Thus, the clinician, researcher, and molecular biologist all need ways to approach the now well over 400 known conditions that fall into this disorder grouping. No classification is satisfactory for all needs and approaches. Thus, we will suggest several ways to approach classification from a historical perspective.

Over time it became clear that an approach separating intrinsic etiologies from extrinsic was useful. Intrinsic conditions includes those disorders arising because of something in the embryo/fetus not developing or functioning correctly (muscle, metabolic disorders, nerve, myelin, central nervous system, etc.). Even severe fetal hypotonia can lead to contractures in some individuals (Haliloglu & Topaloglu, 2013). Extrinsic disorders included a variety of effects, such as maternal (uterine structural anomalies, illnesses, and teratogens). However, there are clearly other extrinsic environmental problems such as drugs, infections, or twins limiting space that could lead to MCCs.

2 | CLINICAL CLASSIFICATION

For the clinician, a useful approach has been to start by distinguish those with only affected limbs, from those with affected limbs plus other body areas, and from those with central nervous system involvement, intellectual disability, or lethality. (Hall, 2013, 2014a) However, as many gene mutations began to be uncovered and individuals in the same family with the same mutation began to be seen in more than one of the groupings, other approaches have been useful (Kimber, Tajsharghi, Kroksmark, Oldfors, & Tulinius, 2012), such as distinguishing amyoplasia, the distal arthrogryposes, the pterygium syndromes, fetal akinesia sequence, the X-linked AMC syndromes, and the effects of hypomobility (Bamshad, Van Heest, & Pleasure, 2009; Beecroft et al., 2018; Hall, 2014a; Hunter et al., 2015; Kimber et al., 2012; Nayak et al., 2014).

Clinicians often find unique and unusual physical signs helpful in identifying specific disorders; thus, lists of unique features (such as deafness or skin abnormalities) aid in making specific diagnoses (Hall, 2013, 2019). These unusual or rare physical findings also help the clinician reflect on the natural history and many interacting genes affecting the disorder.

Also over time, it became clear that many secondary deformations occurred because of lack of fetal movement, such as small jaw and trismus, high bridge of the nose, skin changes (such as edema, pterygium, and dimples), thin osteoporotic bones and abnormal joint surfaces, short gut with immobility, small immature lungs, torticollis, muscle atrophy, and scoliosis. All of the above deformations together are called fetal akinesia deformation sequence and are more severe the earlier the lack of movement has occurred (Ravenscroft et al., 2011).
3 | GENETIC CLASSIFICATION

Another approach to classification is to separate genetic causes from nongenetic (even though maternal uterine structural, maternal drug metabolism, or maternal metabolic causes may have a genetic component) (Darin et al., 2002; Hall et al., 2017). This approach has been very productive when applying whole genome sequencing with triads including mother and father’s analysis as well. This has led to identification of many dominantly inherited conditions (often occurring spontaneously and associated with advanced paternal age), and many recessively inherited conditions, particularly in consanguineous families. As more and more gene mutations have been found associated with AMC, it has become useful to group the genes by their function, and consequently, Gene ontology has been used to sort the newly identified genes, which of course normally lead to proteins, into functional categories and pathways. Gene Ontology analysis includes identifying biological processes, molecular function, and cellular components (Hall & Kiefer, 2016; Kiefer, 2019) in this volume. The 402 now described genes with mutations related to AMC, mainly fall into 19 clusters—which will hopefully help to understand normal fetal movement and reveal pathways that can lead to better understanding and potentially treatment in the future. Since genes often have more than one function and are expressed slightly differently in different tissues, the complex and interactive effects of gene mutations are just beginning to be appreciated.

The frustration at this point in time is that some genes have several domains with different functions, so different mutations in the same gene can lead to very different clinical phenotypes. In addition, the same mutation may give very different phenotypes in different family members, probably related to modifying genes interacting along the biochemical pathway. In fact, one mutation may be inherited as a dominant condition in one family, while a different mutation in the same gene is inherited as an autosomal recessive condition in another family. Thus, although Gene Ontology is an exciting approach, much more must be learned about the pathways and their control before most specific treatments will be available (Wong, 1997).

Since genes reside on chromosomes, deletions or duplications of chromosomal regions containing an important gene or region of control can affect fetal movement. Thus, chromosomal microarray evaluation may be appropriate, particularly in individuals with AMC, intellectual disability, and multiple or minor congenital anomalies.

4 | CLASSIFICATION BY ETIOLOGY

Still another approach has been to classify conditions by the tissue that leads to the decreased fetal movement. Traditionally, these have been classified as neuropathic including both structural and functional nerve abnormalities; myopathic including structural and functional abnormalities of muscle as well as metabolic disorders which affect muscle; neuromuscular junction abnormalities; connective tissue problems including tendons, joints, and even bones; myelin dysplasia and deficiencies; abnormalities of the central nervous system including both structural brain and spinal cord anomalies; and metabolic/inborn errors that affect fetal movement. However, that approach does not include maternal factors which are clearly known to affect fetal movement such as infections (think Zika); maternal immune reactions such as myasthenia gravis; maternal intake of drugs such as cocaine which affects vasculature and curare which affects nerve function; uterine structural abnormalities; uterine fibroids which decrease the space for fetal movement as do twins and other multiples; metabolic disorders that lead to multiple tissue involvement; and finally oligohydramnios which also decreases the space for the fetus to move and affects fetal skin (Hall, 2014b).

The prenatal diagnostician clearly needs an algorithm to provide families and physicians with useful information. Better approaches to prenatal diagnosis will lead to improved recognition prior to third trimester, which in turn should lead to trials of in utero therapy to increase fetal movement (Rink, 2011). However, until the rate of prenatal diagnosis improves in general obstetrical care (see Filges in this volume), useful options are not available.

Thus, a newer approach has been to separate/classify a specific condition as intrinsic (caused by problems within the fetus) or extrinsic (extra-fetal) and then add another layer, such as tissue involvement. This approach may make identifying the underlying mechanism easier, or at least lead to a logical order for laboratory testing.

5 | FUNCTIONAL CLASSIFICATION

The orthopedists and rehabilitation specialists wish for a classification of function, including gross motor (range of motion, position and severity of contractures, and which areas of the body are involved) and indications of self-care and mobility (Aroojis et al., 2005). This in turn will lead to best treatments, natural history, and long-term outcomes data.

6 | CONCLUSION

It is important to keep in mind that all of the disorders associated with congenital contractures seem to occur secondary to decreased fetal movement; thus, understanding the process(es) that leads to increased connective tissue around the fetal joint is important for sorting out all of these disorders. The longer the decreased movement the more severe are these connective tissue related contractures and the more secondary deformations that occur. This means there is a common underlying mechanism that begs to be understood.

Although the third International Arthrogryposis Conference called for the development of a classification system, the field seems to still be in transition. At present, there is no fully comprehensive classification system for AMC, but rather several different approaches that often overlap. The idea is that a useful classification would aid in diagnosis, definition of natural history, recognition of pathways and modifying genes, and potentially early and improved therapies. At this time, a multilayered approach seems useful.

Moving forward will require a multidisciplinary collaboration, as well as engagement of researchers, clinicians, and AMC families. It is possible that one classification system cannot address all these needs.
Clues from the systems used in other rare disorders may help. This issue needs to continue to be addressed by the international AMC community.

**ORCID**

Judith G. Hall  https://orcid.org/0000-0001-5062-491X
Klaus Dietrich  https://orcid.org/0000-0002-4362-4062

**REFERENCES**


REFERENCES


**AUTHOR BIOGRAPHIES**

**Dr. J. G. Hall** is a clinical geneticist and pediatrician. She trained at Wellesley College, the University of Washington School of Medicine, and Johns Hopkins Hospital. She was the Chair of Pediatrics at UBC and BC Children’s Hospital from 1990 to 2000. She is presently Professor Emerita of Pediatrics and Medical Genetics at the University of British Columbia based at Children’s & Women’s Health Centre of British Columbia in Vancouver, BC, Canada. Her areas of research interest are human congenital anomalies, natural history of genetic disorders, and nontraditional mechanisms of genetic disease.

**Eva Kimber, MD, PhD.** Specialist in pediatrics and in pediatric neurology. He completed Dissertation at the Institution of Clinical Sciences, Department of Pediatrics, University of Gothenburg 20091106: Arthrogryposis. Causes, Consequences and Clinical Course in Amyoplasia and Distal Arthrogryposis. He finished Doctor of Medicine at 2010. From 1986 to 1996, resident in pediatrics and in pediatric neurology and habilitation in Västerås central hospital, Uppsala University Hospital and Lund University Hospital. From 1996 to 1997, consultant at the department of Clinical Genetics, Uppsala University Hospital, project for competence center for children with multiple congenital malformations and center for Down syndrome with multiple organ problems. From 1997 to 1998 specialist/consultant at the department of child neurology, Lund University Hospital including project for inventory and care programs for children with neuromuscular disorders in Skåne, southern Sweden. From 1999 to 2014 senior consultant pediatric neurologist at the department of child neurology, Uppsala University Children’s Hospital, with special responsibility and head of regional team for Neuromuscular disorders, development of and participation in multidisciplinary team for investigation and treatment of long-term pain and functional disorders, and participation in team for Neurometabolic disorders. Participation in work regarding gender equality at the Children’s hospital and in the Uppsala University Hospital central group for equality issues. From 2002 and presently also recurrent work at the Lapland Pediatric Clinic, Gällivare and from 2014–2018 work at Mora Children’s Habilitation Center. From January 2014 and until January 2017 head of the Swedish Neuropediatric Society. From January 2015 senior consultant pediatric neurologist at Sahlgrenska University Hospital, Queen Silvia Children’s Hospital and Regional Habilitation Center, Gothenburg, presently part time working with specialist arthrogryposis team. Ongoing research interest in arthrogryposis.

Klaus Dieterich is Assistant Professor in Medical Genetics at the University Hospital Grenoble Alpes, CHUGA/France. He obtained his MD in 2008 and his PhD in 2013, the latter working especially on ECEL1 related arthrogryposis. He is currently head of the pediatric and adult arthrogryposis clinic and the neuromuscular clinic at CHUGA. His main clinical interest lies in the multidisciplinary and patient centered management of patients with arthrogryposis. His research interest focuses on the precise molecular, clinical, functional and imaging description of entities with arthrogryposis.

How to cite this article: Hall JG, Kimber E, Dieterich K. Classification of arthrogryposis. Am J Med Genet Part C 2019; 181C:300-303. https://doi.org/10.1002/ajmg.c.31716